Literature DB >> 15158930

DSM-IV mental disorders and neurological complications in children and adolescents with human immunodeficiency virus type 1 infection (HIV-1).

D Misdrahi1, G Vila, I Funk-Brentano, M Tardieu, S Blanche, M C Mouren-Simeoni.   

Abstract

AIM: - To study the types of psychiatric problem encountered in children infected with the human immunodeficiency virus (HIV) and their relationship to central nervous system disorder and the severity of infection.
METHODS: - 17 HIV-infected children presenting with psychiatric problems were included. Mental disorders were evaluated according to DSM-IV criteria. Neurological disorders and progressive encephalopathy (presence or absence) diagnosis were evaluated by clinical and radiological examination. The severity of infection was assessed by the percentage of CD4 lymphocytes.
RESULTS: - The most frequent diagnoses were major depression (MDD: 47%) and attention deficit hyperactivity disorder (ADHD: 29%). Major depression diagnosis was significantly associated with neuroimaging or clinical neurological abnormalities (p < 0.01). In contrast, no association was found between hyperactivity diagnosed according to DSM-IV criteria and central nervous system disorder. Percentage of CD4 lymphocytes were close to 0 for more than 80% of children presenting with psychiatric complications.
CONCLUSION: - The very low % of CD4 lymphocytes of these children suggest that the appearance of a psychiatric complication should be regarded as a factor indicating severe HIV infection. Depressive disorders may be a clinical form of encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158930     DOI: 10.1016/j.eurpsy.2003.06.009

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  16 in total

1.  Human immunodeficiency virus disease severity, psychiatric symptoms, and functional outcomes in perinatally infected youth.

Authors:  Sharon Nachman; Miriam Chernoff; Paige Williams; Janice Hodge; Jerry Heston; Kenneth D Gadow
Journal:  Arch Pediatr Adolesc Med       Date:  2012-06-01

2.  Psychotropic medication use in human immunodeficiency virus-infected youth receiving treatment at a single institution.

Authors:  Lori Wiener; Haven Battles; Celia Ryder; Maryland Pao
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-12       Impact factor: 2.576

3.  The HIV experience: youth identified barriers for transitioning from pediatric to adult care.

Authors:  Lori S Wiener; Brie-Anne Kohrt; Haven B Battles; Maryland Pao
Journal:  J Pediatr Psychol       Date:  2009-12-29

4.  Psychological symptoms among 2032 youth living with HIV: a multisite study.

Authors:  Larry K Brown; Laura Whiteley; Gary W Harper; Sharon Nichols; Amethys Nieves
Journal:  AIDS Patient Care STDS       Date:  2015-01-13       Impact factor: 5.078

Review 5.  Treatment of psychiatric disorders in children and adolescents with HIV/AIDS.

Authors:  Tami D Benton
Journal:  Curr Psychiatry Rep       Date:  2010-04       Impact factor: 5.285

6.  Profiles of Risk Among HIV-Infected Youth in Clinic Settings.

Authors:  M Isabel Fernández; Heather C Huszti; Patrick A Wilson; Shoshana Kahana; Sharon Nichols; René Gonin; Jiahong Xu; Bill G Kapogiannis
Journal:  AIDS Behav       Date:  2015-05

7.  A Prospective Longitudinal Study of Mental Health Symptoms Among Perinatally HIV-Infected and HIV-Exposed but Uninfected Urban Youths.

Authors:  Massy Mutumba; Jose A Bauermeister; Katherine S Elkington; Amelia Bucek; Curtis Dolezal; Cheng-Shiun Leu; Claude A Mellins
Journal:  J Adolesc Health       Date:  2016-02-09       Impact factor: 5.012

Review 8.  HIV in adolescents: what we know and what we need to know.

Authors:  Tami D Benton; Judith A Ifeagwu
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

9.  YY1 and FoxD3 regulate antiretroviral zinc finger protein OTK18 promoter activation induced by HIV-1 infection.

Authors:  James L Buescher; Lindsey B Martinez; Shinji Sato; Satoshi Okuyama; Tsuneya Ikezu
Journal:  J Neuroimmune Pharmacol       Date:  2008-11-25       Impact factor: 4.147

Review 10.  The ART of HIV therapies: dopaminergic deficits and future treatments for HIV pediatric encephalopathy.

Authors:  Katy M Webb; Charles F Mactutus; Rosemarie M Booze
Journal:  Expert Rev Anti Infect Ther       Date:  2009-03       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.